Construction and Evaluation of Chitosan-Based Nanoparticles for Oral Administration of Exenatide in Type 2 Diabetic Rats.

Polymers (Basel) · 2022 · PMC9183037 · PMID 35683851

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

In Vivo Blood Exenatide Level and Bioavailability As shown in Figure 5 c, exenatide injected subcutaneously reached peak drug concentration at 0.5 h and showed a decreasing trend at the subsequent time, with an area of 35,119 ± 1303 under the curve.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.